Compare Heron Therapeutics Inc (HRTX) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Tidewater Inc — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Tidewater Inc trades at $78.18 (market cap $3.75B). The key difference: Tidewater Inc is far larger — about 41× Heron Therapeutics Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | TDW | |
|---|---|---|
Market Cap | $91.46M | $3.75B |
Sector | Health | Utilities |
52-Week High | $1.96 | $91.12 |
52-Week Low | $0.39 | $47.29 |
Enterprise Value | $189.36M | $3.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.48, up 2.06% today, with a bullish technical signal but mixed earnings performance. The company reported Q1 2026 revenue of $151M but missed EPS estimates with a $0.04 loss. Despite negative net income margins, analyst consensus remains overwhelmingly bullish with 18 buy ratings. Recent patent litigation developments and seasonal pressures have impacted quarterly results.
Outlook remains challenged by ongoing losses and competitive pressures, though strong analyst support suggests potential upside if execution improves. Key risks include patent litigation outcomes, cash flow sustainability, and ability to achieve profitability. The stock's low price presents speculative opportunity but requires careful risk management.
Tidewater (TDW) trades at $75.43, down 0.51% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent earnings show mixed results, missing Q1 2026 estimates with $0.12 EPS versus $0.75 expected. The company maintains strong profitability with a 22.16% net margin and 24.03% ROE, while valuation ratios like a P/E of 12.72 suggest potential undervaluation. News highlights include the acquisition of Tidewater Logistics by FTAI Infrastructure in June 2026.
The outlook is cautiously optimistic due to solid fundamentals and analyst buy ratings, but risks include earnings volatility and sector sensitivity. Upside potential hinges on execution improvements, while downside risks stem from energy market fluctuations and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
